Juho Jalkanen
Overview
Explore the profile of Juho Jalkanen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
310
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmauch E, Ojanen J, Galani K, Jalkanen J, Harju K, Hollmen M, et al.
Nucleic Acids Res
. 2024 Dec;
53(1.
PMID: 39656909
Single-nuclei RNA sequencing remains a challenge for many human tissues, as incomplete removal of background signal masks cell-type-specific signals and interferes with downstream analyses. Here, we present Quality Clustering (QClus),...
2.
Rantasalo V, Laukka D, Nikulainen V, Jalkanen J, Gunn J, Kiviniemi T, et al.
Clin Transl Sci
. 2024 Sep;
17(10):e70036.
PMID: 39344403
Aortic calcification-a marker of advanced atherosclerosis in large arteries-associates with cardiovascular mortality and morbidity. Little is known about the soluble inflamJarmatory profiles involved in large artery atherosclerosis. We investigated the...
3.
Maaniitty E, Sinisilta S, Jalkanen J, Vasankari T, Biancari F, Gunn J, et al.
Int J Cardiol Cardiovasc Risk Prev
. 2024 Aug;
22:200307.
PMID: 39091640
Background: Systemic inflammation has a critical role in the development of symptomatic coronary artery disease (CAD). Identification of inflammatory pathways may provide a platform for novel therapeutic approaches. We sought...
4.
Maaniitty E, Jalkanen J, Sinisilta S, Gunn J, Vasankari T, Biancari F, et al.
Sci Rep
. 2024 Jul;
14(1):17269.
PMID: 39068298
Chronic inflammation plays a crucial role in coronary artery disease (CAD), but differences in specific cytokine profiles between acute coronary syndrome (ACS) and stable CAD remain unknown. We investigated cytokine...
5.
Linna-Kuosmanen S, Schmauch E, Galani K, Ojanen J, Boix C, Ord T, et al.
Cell Rep Med
. 2024 May;
5(5):101556.
PMID: 38776872
Cardiovascular disease plays a central role in the electrical and structural remodeling of the right atrium, predisposing to arrhythmias, heart failure, and sudden death. Here, we dissect with single-nuclei RNA...
6.
Williamson J, Spicer A, Louramo E, Jalkanen J
Drug Discov Today
. 2024 Feb;
29(4):103919.
PMID: 38365000
Biotechnology and small pharma companies must recognize the opportunity presented by FDA Breakthrough Therapy Designation (BTD) to expedite drug development for serious conditions. This paper evaluates BTD economic and developmental...
7.
Viikinkoski E, Aittokallio J, Lehto J, Ollila H, Relander A, Vasankari T, et al.
J Cardiothorac Vasc Anesth
. 2024 Jan;
38(3):709-716.
PMID: 38220516
Objectives: Cardiac surgery induces systemic inflammatory response syndrome (SIRS), leading to higher morbidity and mortality. There are no individualized predictors for worse outcomes or biomarkers for the multifactorial, excessive inflammatory...
8.
Koskinen A, Aittokallio J, Gunn J, Lehto J, Relander A, Viikinkoski E, et al.
JTCVS Open
. 2024 Jan;
16:602-609.
PMID: 38204615
Objective: Patients undergoing heart surgery are at high risk of postoperative fluid accumulation due to long procedures and cardiopulmonary bypass. In the present study, we sought to investigate the prevalence...
9.
Rannikko J, Verlingue L, de Miguel M, Pasanen A, Robbrecht D, Skytta T, et al.
Cell Rep Med
. 2023 Dec;
4(12):101307.
PMID: 38056464
Macrophage Clever-1 contributes to impaired antigen presentation and suppression of anti-tumor immunity. This first-in-human trial investigates the safety and tolerability of Clever-1 blockade with bexmarilimab in patients with treatment-refractory solid...
10.
Jalkanen J, Khan S, Elima K, Huttunen T, Wang N, Hollmen M, et al.
Crit Care
. 2023 Mar;
27(1):112.
PMID: 36927455
Background: The use of glucocorticoids has given contradictory results for treating acute respiratory distress syndrome (ARDS). The use of intravenous Interferon beta (IFN β) for the treatment of ARDS was...